

Diabetic Macular Edema: How Intravitreal Advances Can Revolutionize Care
Diabetic macular edema (DME) remains a prominent cause of vision impairment among U.S. diabetic populations, necessitating innovative treatments. Current therapies focus on anti-VEGF injections, yet novel approaches—such as faricimab, higher aflibercept doses, and the Port Delivery System—aim to enhance effectiveness and reduce treatment burdens. Understanding key advancements is crucial for improved patient outcomes. Innovations in […]
3 min read